09:58 AM EST - Cardiol Therapeutics Inc. : Announced that its exclusive manufacturing partner, Dalton Pharma Services, has received a three-year renewal and license amendment of its Cannabis Act Processing License from Health Canada. This renewal and amendment will permit scaled commercial production of Cardiol's high concentration pharmaceutical cannabidiol formulations and their sale to other license holders. Cardiol Therapeutics Inc.
shares T.CRDL are trading down $0.12 at $4.30.
